【摘要】 目的　探讨肿瘤浸润性淋巴细胞 (TIL)对原发性肝癌 (HCC)患者术后细胞免疫功能的影响和临床疗效及半乳糖抗CD3 单克隆抗体 TIL复合物 (Gal Anti CD3 McAb TIL)体外及体内的趋肝性。方法　 (1)对 30例HCC患者术后进行了TIL和重组白介素 2 (rIL 2 )治疗。 (2 )制备半乳糖基抗CD3 单克隆抗体 TIL(McAb TIL)复合物。将TIL和McAb TIL分别与小鼠肝细胞置CO2 孵箱中孵育 ,用倒置相差显微镜观察其趋肝性。将12 5I TIL和12 5I McAb TIL分别经小鼠尾静脉注入 ,观察示踪剂在脏器中的分布。结果　TIL治疗后 ,30例患者外周血rIL 2、T细胞亚群均有上升。 2 4例肝癌根治性切除术患者随访 6～ 48个月无复发。McAb TIL与肝细胞有明显粘附 ,给小鼠静脉注射后 ,TIL和McAb TIL主要在肺中积聚 ,在肝内浓度较低。结论　TIL治疗可能提高HCC患者术后抗肿瘤细胞免疫功能。TIL与半乳糖抗CD3 单克隆抗体结合物体内肝靶向性不明显更多还原

【Abstract】 Objective To evaluate the effect of TILs treatment on postoperative patients with hepatocellular carcinoma （HCC） and the in vitro and in vivo hepatic targeting tendency of a compound of Galactosyl-Anti-CD₃McAb-TILs.Methods Thirty postoperative HCC patients were treated with TILs plus rIL-2. A hepatic targeting carrier, Galactosyl-Anti-mouse-CD₃-monoclonal antibody （Gal-Anti-CD₃-McAb）, was synthesized.Result It was found that the peripheral blood level of IL-2 and T cell subset increased in all the 30 patients treated by TILs.24 HCC cases undergoing hepatectomy were treated by TILs therapy, and follow-up of 6 to 48 months found no recurrence. In an murine experiment a combination of TIL & Galactosyl-Anti-CD₃McAb-TIL tended to aggregate in lung while infused from peripheral vein. Its hepatic targeting tendency was unremarkable. Conclusion Postoperative use of TILs increased patients’ antitumor immunity, prolongs the survival, while galactosyl-anti-CD₃McAb-TIL does not show a satisfactory hepatic target tendency.更多还原